Advertisement

Guidelines for the Prevention of Cardiovascular Risk in HIV-Infected Patients Treated with Antiretroviral Drugs

  • D. Scevola
  • L. Oberto
  • G. Barbarini
  • G. Barbaro

Abstract

Highly active antiretroviral therapy (HAART) has decreased by two-thirds [1] the lethality of AIDS and opportunistic infections. However, the improved survival of HIV patients receiving HAART has become associated with metabolic complications including insulin resistance, impaired glucose tolerance, loss of skeletal muscle mass (sarcopenia) and performance, osteopenia, lipid abnormalities such as dyslipidemia and body-fat distribution [2–19], which increase cardiovascular morbidity, compromising the patient’s quality of life and the efficacy of HAART. As a consequence of prolonged survival and the direct effect of HAART [16], AIDS is changing from a “slim disease” to a “lipodystrophic disease” [20] and the care of the HIV-infected patients “has shifted from prevention and treatment of opportunistic infections and malignancies to management of the metabolic and related complications”[17]. The risk of cardiovascular disease (CVD) in HIV patients is increased two- to three-fold by disturbances in fat metabolism [15, 17]. New strategies addressed to prevent and manage such emerging disorders, including muscle and bone disorders (sarcopenia and osteopenia) [17, 21, 22], are needed. Moreover, coronary heart disease (CHD) is the leading cause of death and a common cause of morbidity in Western countries. Approximately 14 million Americans have CHD, according to NHANES III data [23]. Annually, about 1.1 million of them experience a heart attack and about 500,000 die from CHD (Fig. 1).

Keywords

Resistance Training Resistance Exercise Skeletal Muscle Mass Rest Metabolic Rate Megestrol Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Palella FJ, Delaney KM, Mooreman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853–860CrossRefPubMedGoogle Scholar
  2. 2.
    Dubè MP, Sattler FR (1998) Metabolic complications of antiretroviral therapies. AIDS Clinical Care 10:41–44PubMedGoogle Scholar
  3. 3.
    Sullivan AK, Nelson MR (1997) Marked hyperlipidaemia on ritonavir. AIDS 11:938–939CrossRefPubMedGoogle Scholar
  4. 4.
    Hengel RL, Watts NB, Lennox JL (1997) Benign symmetric lipomatosis associated with protease inhibitors. Lancet 350:1596CrossRefPubMedGoogle Scholar
  5. 5.
    Miller KD, Jones E, Yanovski JA et al (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351:871–875CrossRefPubMedGoogle Scholar
  6. 6.
    Carr A, Samaras K, Burton S et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51–F58CrossRefPubMedGoogle Scholar
  7. 7.
    Lo JC, Mulligan K, Tai VW et al (1998) “Buffalo hump” in men with HIV-infection. Lancet 351:867–870CrossRefPubMedGoogle Scholar
  8. 8.
    Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitorassociated peripheral liopdystrophy, hyperlipidemia, and insulin resistance. Lancet 352:1881–1883CrossRefGoogle Scholar
  9. 9.
    Rosenberg HE, Mulder J, Sepkowitz K et al (1998) “Protease-paunch” in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998, abstract 408Google Scholar
  10. 10.
    Kotler DP, Rosenbaum KB, Wang J et al (1998) Alterations in body fat distribution in HIVinfected men and women. Twelfth World AIDS Conference, Geneva, Switzerland, June-July 1998, abstract 32173Google Scholar
  11. 11.
    Engelson ES, Kotler DP, Tan YX et al (1998) Altered body fat distribution in HIV infection: regional body composition measurements by whole body MRI and DXA scans. Twelfth World AIDS Conference, Geneva, Switzerland, June-July 1998, abstract 32181Google Scholar
  12. 12.
    Boyle BA (1999) Lipodystrophy: A new phenomenon? AIDS Reader 9:15–17PubMedGoogle Scholar
  13. 13.
    Gervasoni C, Ridolfo AL, Trifirò G et al (1999) Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13:465–471CrossRefPubMedGoogle Scholar
  14. 14.
    Bernasconi E (1999) Metabolic effects of protease inhibitor therapy. AIDS Reader 9:254–269PubMedGoogle Scholar
  15. 15.
    Grinspoon S, Carr A (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352:48–62CrossRefPubMedGoogle Scholar
  16. 16.
    Mangili A, Murman DH, Zampini AM, Wanke CA (2006) Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from nutrition for healthy living cohort. Clin Infect Dis 42:836–842CrossRefPubMedGoogle Scholar
  17. 17.
    Morse CG, Kovacs JA (2006) Metabolic and skeletal complications of HIV infection: the price of success. JAMA 296:844–854CrossRefPubMedGoogle Scholar
  18. 18.
    Authier FJ, Chariot P, Gherardi RK (2005) Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 32:247–260CrossRefPubMedGoogle Scholar
  19. 19.
    Scott WB, Oursler KK, Katzel LI et al (2007) Central activation, muscle performance, and physical function in men infected with human immunodeficiency virus. Muscle Nerve 36(3) (published online: 6 June 2007). doi:10.1002/mus.20832Google Scholar
  20. 20.
    Scevola D, Di Matteo A, Giglio O, Uberti F (2006) HIV Infection-related cachexia and lipodystrophy In: Mantovani G (ed) Cachexia and wasting: a modern approach. Springer, Milan, pp 407–428CrossRefGoogle Scholar
  21. 21.
    Scevola D, Di Matteo A, Uberti F et al (2000) Reversal of cachexia in patients treated with potent antiretroviral therapy. AIDS Reader 10:365–375PubMedGoogle Scholar
  22. 22.
    Henry K, Zackin R, Dube M et al (2001) Metabolic status and cardiovascular disease risk for a cohort of HIV-1-infected persons durably suppressed on an indinavir-containing regimen(ACTG 372A). Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, ILL, 4-8 February 2001, abstract 656Google Scholar
  23. 23.
    Adams PF, Marano MA (1995) Current estimates from the National Health Interview Survey, 1994, National Center for Health Statistics. Vital Health Stat 10:193Google Scholar
  24. 24.
    Anonymous (1999) Healthy people 2010: draft for public comment. Department of Health and Human Services, Washington, DCGoogle Scholar
  25. 25.
    Henry K, Melroe H, Huebesh J et al (1999) Experience with the National Cholesterol Education Program (NCEP) guidelines for the identification and treatment of protease inhibitor related lipid abnormalities: results of a prospective study. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, ILL, 31 Jan-4 Feb 1999, abstract 671Google Scholar
  26. 26.
    Grunfeld C, Feingold KR (1992) Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 5:329–337Google Scholar
  27. 27.
    Lonergan JT, Havlir D, Barber E, Mathews WC (2001) Incidence and outcome of hyperlactatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containing regimens. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, ILL, 4-8 February 200, 1 abstract 624Google Scholar
  28. 28.
    Scevola D, Bottari G, Oberto L, Faggi A (1996) AIDS cachexia: basics and treatment. In: Ruf B, Pohle HD, Goebel FD, L’age M (eds) HIV-Infektion, Pathogenese, Diagnostik und Therapie. Socio-medico Verlag, Wessobrunn, Germany, pp 281–327Google Scholar
  29. 29.
    Oursler KK, Sorkin JD, Smith B, Katzel LI (2006) Reduced aerobic capacity and physical functioning in older HIV-infected men. AIDS Res Hum Retroviruses 22:1113–1121CrossRefPubMedGoogle Scholar
  30. 30.
    Watson RR (ed) (2004) AIDS and heart disease. Informa Healthcare, London, 496 ppGoogle Scholar
  31. 31.
    Melchior JC, Salmon D, Rigaud D et al (1991) Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 53:437–441PubMedGoogle Scholar
  32. 32.
    Grunfeld C, Pang M, Shimizu L et al (1992) Resting energy expenditure, caloric intake and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 55:455–460PubMedGoogle Scholar
  33. 33.
    Shevitz AH (2000) Resting energy expenditure in the HAART era. AIDS Reader 10:539–544PubMedGoogle Scholar
  34. 34.
    WHO (1986) Working group on the use and interpretation of anthropometric indicators of nutritional status. Bull WHO 64:929–941Google Scholar
  35. 35.
    Kotler DP, Rosenbaum K, Wang J, Pearson RN (1999) Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 20:228–237PubMedGoogle Scholar
  36. 36.
    Scevola D (1993) La cachessia nelle malattie infettive e neoplastiche. Edizioni Medico Scientifiche, Pavia, ItalyGoogle Scholar
  37. 37.
    Scevola D, Giglio O, Scevola S (2006) Treatment of AIDS anorexia-cachexia syndrome and lipodystrophy. Mantovani G (ed) In: Cachexia and wasting: a modern approach. Springer, Milan, pp 429–456CrossRefGoogle Scholar
  38. 38.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRefGoogle Scholar
  39. 39.
    Scevola D, Di Matteo A, Lanzarini P et al (2003) Effect of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 17(S1):S123–S129PubMedGoogle Scholar
  40. 40.
    Volberding PA, Murphy RL, Barbaro G et al (2003) The Pavia consensus statement. AIDS 17(S1):S170–S179PubMedGoogle Scholar
  41. 41.
    Dubé MP, Stein JH, Aberg JA et al (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS clinical trials group. Clin Inf Dis 37:613–627CrossRefGoogle Scholar
  42. 42.
    Williams MA, Haskell WL, Ades PA et al (2007) Resistance exercise in individuals with and without cardiovascular disease: 2007 update. A scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation 116:572. doi:10.1161/CIRCULATIONAHA.107.185214CrossRefPubMedGoogle Scholar
  43. 43.
    Pollock ML, Vincent KR (1996) Resistance training for health. In: The President’s Council on Physical Fitness and Sports Research Digest, series 2, no. 8Google Scholar
  44. 44.
    Smit E, Crespo CJ, Semba RD et al (2006) Physical activity in a cohort of HIV-positive and HIVnegative injection drug users. AIDS Care 18:1040–1045CrossRefPubMedGoogle Scholar
  45. 45.
    American College of Sports Medicine (2006) ACSM’s guidelines for exercise testing and prescription, 7th edn., Lippincott, Baltimore, MDGoogle Scholar
  46. 46.
    Brochu M, Savage P, Lee M et al (2002) Effects of resistance training on physical function in older disable women with coronary heart disease. J Appl Physiol 92:672–678CrossRefPubMedGoogle Scholar
  47. 47.
    Brown SP, Miller WC, Eason JM Exercise (2006) Physiology: basis of human movement in health and disease. Lippincott, Baltimore, MD, pp 98–124Google Scholar
  48. 48.
    Ibanez J, Izquierdo M, Arguelles I et al (2005) Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 28:662–667CrossRefPubMedGoogle Scholar
  49. 49.
    Sax PE (2006) Strategies for management and treatment of dyslipidemia in HIV/AIDS. AIDS Care 18:149–157CrossRefPubMedGoogle Scholar
  50. 50.
    Scevola D, Di Matteo A, Giglio O, Uberti F (2007) Starvation: social, voluntary, and involuntary causes of weight loss. In: Mantovani G (ed) Cachexia and wasting: a modern approach. Springer, Milan, pp 149–160Google Scholar
  51. 51.
    Scevola D, Di Matteo A, Giglio O, Scevola S (2006) Nutritional status assessment. In: Mantovani G (ed) Cachexia and wasting: a modern approach. Springer, Milan, pp 93–110CrossRefGoogle Scholar
  52. 52.
    Barrios A, Blanco F, Garcìa-Benayas T et al (2002) Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 16:2079–2081CrossRefPubMedGoogle Scholar
  53. 53.
    Von Roenn JH (1994) Management of HIV-related body weight loss. Drugs 47:774–783CrossRefGoogle Scholar
  54. 54.
    Scevola D, Bottari G, Zambelli A et al (1992) Trattamento dietetico ed ormonale dei deficit nutrizionali nell’AIDS. Clin Dietol 19:127–140Google Scholar
  55. 55.
    Tisdale M, Beck SA (1991) Inhibition of tumour induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 41:103–107CrossRefPubMedGoogle Scholar
  56. 56.
    Kardinal CG, Loprinzi CL, Schaid DJ et al (1990) A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657–2662CrossRefPubMedGoogle Scholar
  57. 57.
    Scevola D, Zambelli A, Bottari G et al (1991) Appetite stimulation and body weight gain with medroxyprogesterone acetate in AIDS anorexia and cachexia. Farmaci Terapia 3:77–83Google Scholar
  58. 58.
    Scevola D, Parazzini F, Negri C, Moroni M (1995) Efficacy and safety of high-dose MPA treatment of AIDS cachexia: the Italian multicentre study. Fourth Congress of the European Association for Palliative Care, Barcelona, 6–9 December 1995, abstracts book, pp 443–447Google Scholar
  59. 59.
    Scevola D, Bottari G, Oberto L et al (1995) A double-blind-placebo controlled trial of megestrol acetate on caloric intake and nutritional status in AIDS cachexia. Fourth Congress of European Association for Palliative Care, Barcelona, 6-9 December 1995, abstracts book, pp 427-437Google Scholar
  60. 60.
    Rondanelli M, Solerte SB, Fioravanti M et al (1997) Circadian secretory pattern of growth hormone, insulin-like growth factor type I, cortisol, adrenocorticotropic hormone, thyroid-stimulating hormone, and prolactin during HIV infection. AIDS Res Hum Retroviruses 14:1243–1249CrossRefGoogle Scholar
  61. 61.
    Scevola D, Bottari G, Oberto L et al (1995) Megestrol acetate (MA) and growth hormone (rHGH) as combined therapy for AIDS cachexia. Fourth Congress of European Association for Palliative Care, Barcelona, 6–9 December 1995, abstracts book, pp 438–442Google Scholar
  62. 62.
    Wanke C, Gerrior J, Kantaros J et al (1999) Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13:2099–2103CrossRefPubMedGoogle Scholar
  63. 63.
    Saint-Marc T, Touraine JL (1999) Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, ILL, 31 Jan-4 Feb 1999, abstract 672Google Scholar
  64. 64.
    Walli RK, Michl GM, Bogner JR et al (1999) Effects of the PPAR-Activator troglitazone on protease inhibitor associated peripheral insulin resistance. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, ILL, 31 Jan-4 Feb 1999, abstract 673Google Scholar
  65. 65.
    Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D et al (2004) No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363:429–38CrossRefPubMedGoogle Scholar
  66. 66.
    Torres R, Unger K (1999) The effect of recombinant human growth hormone on proteaseinhibitorassociated fat maldistribution syndrome. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, ILL, 31 Jan-4 Feb 1999, abstract 675Google Scholar
  67. 67.
    Strawford A, Barbieri T, Parks E et al (1999) Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIVrelated weight loss. JAMA 281:1282–1290CrossRefPubMedGoogle Scholar
  68. 68.
    Scevola D, Oberto L, Bottari G, Faggi A (1995) Lipidi e Malattie Infettive. Abstracts Book XII Congresso Nazionale ADI. Torino, Italy, 16–18 November 1995, p 187Google Scholar
  69. 69.
    Scevola D, Bottari G, Oberto L et al (1996) Problemi nutrizionali del paziente AIDS e strategie terapeutiche. Quad Cure Palliat (S1):51–64Google Scholar
  70. 70.
    Lauretani F, Russo CR, Bandinelli S et al (2003) Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 95:1851–1860PubMedGoogle Scholar
  71. 71.
    Amsterdam EA (1997) Exercise in cardiovascular health and disease. Yorke, New YorkGoogle Scholar
  72. 72.
    Smith BA, Neidig JL, Nickel JT et al (2001) Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS 15:693–701CrossRefPubMedGoogle Scholar
  73. 73.
    Montoye HJ (1975) Physical activity and health: an epidemiologic study of an entire community. Prentice-Hall, Englewood Cliffs, NJGoogle Scholar
  74. 74.
    Katch FI, Freedson PS, Jones CA et al (1985) Evaluation of acute cardiorespiratory responses to hydraulic resistance exercise. Med Sci Sports Exerc 17:168–173PubMedGoogle Scholar
  75. 75.
    Crow RS, Rantahargiu PM, Prineas RJ et al (1986) Risk factors, exercise fitness and electrocardiographic response to exercise in 12,866 men at risk of symptomatic coronary heart disease. Am J Cardiol 57:1075–1082CrossRefPubMedGoogle Scholar
  76. 76.
    Pollock M, Gaesser G, Butcher J et al (1998) The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness and flexibility in healthy adults. Med Sci Sports Exerc 30:975–991CrossRefGoogle Scholar
  77. 77.
    Stringer WW, Berezovskaya M, O’Brien WA et al (1998) The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients. Med Sci Sports Exerc 30:11–16PubMedGoogle Scholar
  78. 78.
    Beniamini Y, Rubenstein JJ, Faigenbaum AD et al (1999) High-intensity strength training of patients enrolled in an outpatient cardiac rehabilitation program. J Cardiopulm Rehabil 19:8–17CrossRefPubMedGoogle Scholar
  79. 79.
    Braith RW, Stewart KJ (2006) Resistance exercise training: its role in the prevention of cardiovascular disease. Circulation 113:2642–2650CrossRefPubMedGoogle Scholar
  80. 80.
    McCartney N, McKelvie RS, Haslam DR, Jones NL (1991) Usefulness of weightlifting training in improving strength and maximal power output in coronary artery disease. Am J Cardiol 67:939–945CrossRefPubMedGoogle Scholar
  81. 81.
    Maeda S, Miyauchi T, Iemitsu M et al (2004) Resistance exercise training reduces plasma endothelin-1 concentration in healthy young humans. J Cardiovasc Pharmacol 44(suppl1): S443–S446CrossRefPubMedGoogle Scholar
  82. 82.
    Stewart KJ, Bacher AC, Turner K et al (2005) Exercise and risk factors associated with metabolic syndrome in older adults. Am J Prev Med 28:9–18CrossRefPubMedGoogle Scholar
  83. 83.
    Swain DP, Franklin BA (2006) Comparison of cardioprotective benefits of vigorous versus moderate intensity aerobic exercise. Am J Cardiol 97:141–147CrossRefPubMedGoogle Scholar
  84. 84.
    Vincent KR, Vincent HK, Braith RW et al (2002) Resistance exercise training attenuates exerciseinduced lipid peroxidation in the elderly. Eur J Appl Physiol 87:416–423CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • D. Scevola
    • 1
  • L. Oberto
    • 1
  • G. Barbarini
    • 1
  • G. Barbaro
    • 2
  1. 1.Department of Infectious and Tropical DiseasesPoliclinico San Matteo, University of PaviaPaviaItaly
  2. 2.Department of Medical Pathophysiology“Sapienza” University of RomeRomeItaly

Personalised recommendations